Biochemics sec
WebThe treatment that could produce the money for BioChemics to pay down its SEC debt is already being prescribed by doctors associated with “leading medical institutions,” Schlichtmann said. In addition to the $17.2 million BioChemics owes the SEC, Florida-based private equity firm ADEC Private WebBiochemistry or biological chemistry is the study of chemical processes within and relating to living organisms. A sub-discipline of both chemistry and biology, biochemistry may be divided into three fields: structural …
Biochemics sec
Did you know?
WebAug 22, 2024 · According to the SEC complaint, BioChemics, Masiz and co-conspirators were accused of engaging in a fraudulent scheme to sell company securities to approximately 70 investors. The scheme, which ran from 2009 until the middle of 2012, netted at least $9 million. Investors caught up in the scheme resided in 19 different states. WebThe SEC claimed in a 2012 lawsuit that BioChemics and Masiz lied about the status of topical gels that would allow medicine to be absorbed through the skin. They allegedly falsely asserted the...
WebJan 17, 2024 · See SEC v. BioChemics, Inc. et al., No. 12-12324-MLW (D. Mass.). On 8/18/18 the Commission dismissed the claims against Masiz under Section 10 (b) of, and … WebDec 16, 2012 · Three repeat securities law violators teamed up to defraud 70 investors of over $9 million over three years. The complaint claims the defendants sold interests in a privately held biochemical company based on a series of misrepresentations. SEC v. Biochemics, Inc., Civil Action No. 1:12-cv-12324 (D. Mass. Filed Dec. 14, 2012).
WebCompany profile page for BioChemics Inc including stock price, company news, press releases, executives, board members, and contact information WebBiochemists work in industries like agriculture, medical research, biotechnology and nutritional research. Our students go on to positions in research and industry, as well as graduate study in biochemistry, …
WebDeveloper of transdermal drug delivery technology designed to offer treatment for the skin.
WebThe relevant facts trace back to the SEC indictment of BioChemics and BioChemics’s CEO John Masiz for securities fraud in 2012. See SEC v. Biochemics, Inc., 435 F. Supp. 3d 281, 285 (D. Mass. 2024) (appeal dismissed as moot at SEC v. Masiz, No. 19-2206, No. 20-1177, No. 20- grace church gazetteWebMay 23, 2024 · Plaintiffs sought damages for what they claimed was AXIS's breach, under the relevant policy, of its duty to defend them in connection with an investigation conducted by the Securities and Exchange Commission against BioChemics and its officers. chilkoot way whitehorseWebGet free access to the complete judgment in Sec. & Exch. Comm'n v. BioChemics, Inc. on CaseMine. chilkoot trail skagwayWebLaw360, Boston (October 10, 2024, 5:10 PM EDT) -- After dodging a $17 million payment to the U.S. Securities and Exchange Commission, BioChemics Inc. will have to deal with a court-appointed... chilkoot whiskeyWebAug 29, 2024 · According to the complaint, when BioChemics finally did conduct one clinical trial, it misrepresented the results of that trial. The complaint further alleged that Masiz … chilkoot wilderness and wildlife tourWebthe SEC served document subpoenas on Biochemics and Masiz in March 2012 (during the policy period); and the SEC filed an enforcement action against Biochemics, Masiz, and two promoters retained by the company in December 2012 (after the expiration of the policy period). Biochemics notified AXIS of the January and March 2012 subpoenas. grace church ghentWebJan 6, 2015 · Plaintiffs BioChemics, Inc., and John Masiz sued defendant Axis Reinsurance Company (“AXIS”) for defense costs arising out of a Securities and Exchange Commission (“SEC”) investigation and enforcement action under their directors and officers (“D & O”) liability insurance policy. grace church give